Webinars/Videos

In this KOL masterclass on demand video, Prof. Stephen Nicholls will discuss the impact of intensive lipid lowering strategies (statins, evolocumab, alirocumab) on plaque phenotype and progression.

This masterclass on-demand video is designed for health care professionals (cardiologists, lipidologists, diabetes specialists, neurologists) who are interested in learning more on the results of the latest clinical trials (GLAGOV, HUYGENS, PACMAN-AMI) on coronary disease.

Prof. Stephen Nicholls

First published: July 7, 2022  

This ACC highlights video provides insights into novel strategies to lower the levels of triglycerides to reduce triglyceride-associated complications.

First published: June 30, 2022  

In this KOL master class on demand video Prof. Maciej Banach discusses the prevalence and current understanding of statin Intolerance which remains a public health problem currently. He is joined by Prof. Christopher Cannon for a peer-to-peer discussion and to answer audience questions.

This interactive webinar is designed for health care professionals (cardiologists, endocrinologists, lipidologists, neurologists) who are interested in learning more on the latest research, treatment, and clinical management of patients with statin intolerance.

Click here to download the unanswered questions from this webinar.

Prof. Maciej Banach, Prof. Christopher Cannon

First published: June 6, 2022  

In this KOL masterclass on demand video, Prof. Sameer Ellaham will discuss the role of lipoprotein (a) in cardiovascular disease risk and possible ways to manage and treat Lp(a) levels in patients.

This masterclass on-demand video is designed for heath care professionals (cardiologists, lipidologists, diabetes specialists, neurologists) who are interested in learning more on the latest research, treatment, and clinical management of patients with a risk of ASCVD and having an elevated level of Lp(a).

Prof. Sameer Ellaham

First published: April 26, 2022  

Prof Bhatt answers questions received from the audience before and during the live webinar on Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention: The REDUCE-IT Trial.

For the best learning experience, we recommend watching the KOL masterclass on/demand video in addition to this video.

Prof. Deepak Bhatt

First published: March 26, 2022  

In this masterclass on demand video, Prof Bhatt discusses Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention: The REDUCE-IT Trial.
This masterclass on-demand video is designed for health care professionals (cardiologists, endocrinologists, lipidoligists, diabetes specialists, neurologists) who are interested in learning more on the latest research, treatment and clinical management in reducing cardiovascular events with Icosapent Ethyl-Intervention.

Prof. Deepak Bhatt

First published: March 26, 2022  

Prof. Tokgözoğlu answers questions received from the audience during the live webinar on Atherosclerotic Cardiovascular Disease (ASCVD) and dyslipidemia in female patients. For the best learning experience, we recommend watching the KOL masterclass on-demand video in addition to this video.

Prof. Lale Tokgözoğlu

First published: March 7, 2022  

In this KOL masterclass on-demand video, Prof. Lale Tokgözoğlu discusses Atherosclerotic Cardiovascular Disease (ASCVD) and dyslipidemia in female patients with emphasis on female specific risks, course, and management of the disease.

This masterclass on-demand video is designed for health care professionals (cardiologists, endocrinologists, lipidogists, diabetes specialists, neurologists) who are interested in learning more on the latest research, treatment, and clinical management of patients with a history and risk of ASCVD.

Prof. Lale Tokgözoğlu

First published: March 7, 2022  

Editorial Panel Member Prof. Christopher Cannon interviews Prof. Kausik Ray, (President European Atherosclerosis Society and Professor of Public Health and Honorary Consultant Cardiologist, Imperial College London) on the program to roll out the latest PCSK9 inhibitor Inclisiran, first-in-class siRNA to lower cholesterol in the United Kingdom.

To note, the US Food and Drug Administration (FDA) recently approved Inclisiran as an add-on therapy to lower cholesterol among certain high-risk adults on maximally tolerated statin therapy.

Prof. Christopher Cannon, Prof. Kausik Ray

First published: January 10, 2022  

Listen to the first of a free series of webinars brought to you by the Wiley Knowledge Hub on ASCVD and Lipidology.

Prof. Lale Tokgözoğlu, Prof. Chern-En Chiang

First published: December 13, 2021  

Listen to Prof. Lale Tokgözoğlu summarizing the year in Lipids and discussing the highlights from this year’s AHA Scientific Sessions.

Prof. Lale Tokgözoğlu, Prof. Chern-En Chiang

First published: December 13, 2021  

Prof. Chern-En Chiang talks about some of the recent advances in diabetes treatment in patients with ASCVD.

Prof. Lale Tokgözoğlu, Prof. Chern-En Chiang

First published: December 13, 2021